Automated Insulin Delivery: What the Latest Research Shows

A major review of 28 clinical trials found that hybrid closed-loop (HCL) systems—which use continuous glucose monitors and automated pumps to adjust insulin delivery—significantly improve time in target glucose range compared to standard insulin therapy without continuous monitoring.

Among the systems studied, the Minimed 780G achieved the highest percentage of time in target range, followed by Control-IQ, Minimed 670G, CamAPS Fx, and DBLG-1. However, all of these systems outperformed traditional treatment approaches.

A separate analysis of 65 randomized trials involving 3,623 people with Type 1 diabetes found that automated insulin delivery systems increased time in target range by nearly 12 percentage points on average. The benefit was even greater for people who had diabetes for more than 20 years or who already had good baseline blood sugar control.

Importantly, these systems reduced time spent in dangerous low blood sugar ranges. The largest reductions came from the DBLG-1, Minimed 670G, and Minimed 780G systems.

Researchers evaluated whether automated insulin delivery is safe and effective in older adults with Type 1 diabetes—a group at high risk for severe low blood sugar. In a trial of 82 people aged 65 to 86, hybrid closed-loop systems reduced time spent below 70 mg/dL by more than 1 percentage point compared to sensor-augmented pumps alone, while improving time in the target range of 70–180 mg/dL by nearly 9 percentage points.

Pregnant women with Type 1 diabetes face particular challenges, as high blood sugar during pregnancy increases risks of complications for both mother and baby. A recent trial found that closed-loop systems helped pregnant women spend 65% of their time in the pregnancy-specific target glucose range (63–140 mg/dL), compared to 50% in standard care. Safety monitoring showed rates of severe hypoglycemia and diabetic ketoacidosis similar to other insulin therapies.

Across all studies reviewed, automated insulin delivery systems did not increase the risk of severe low blood sugar or diabetic ketoacidosis compared to other insulin-based treatments, suggesting these systems are a safe option for many people with Type 1 diabetes.

Current hybrid closed-loop systems require users to announce meals so the pump can calculate and deliver appropriate insulin. Researchers are now working on next-generation systems designed to work without meal announcements—a feature that could significantly reduce daily management tasks.

One such system in development is the FLEX-AP (Flexible-User-Interaction Multiple-Input Control Architecture). It aims to deliver insulin automatically without meal or exercise information while still allowing people to provide optional input if they choose. The goal is to improve blood sugar control while giving users more flexibility and reducing the mental burden of constant carbohydrate counting.

Scientists are also studying how individual factors—such as dietary fat content and, in women, menstrual cycle phases—affect blood sugar response. Understanding these personalized patterns could help clinicians adjust automated insulin delivery settings to work even better for each person.

While automated insulin delivery systems represent a significant advance in diabetes management, they are tools to support glucose control—not cures. They still require the device to function properly, require regular sensor insertions and infusion set changes, and may involve upfront costs and insurance coverage questions.

The systems studied so far show consistent benefits in reducing time in dangerous low ranges and increasing time in target ranges. However, the choice of which system works best depends on individual circumstances, lifestyle, and preferences. Speaking with a diabetes care team is essential to determine whether an automated system is appropriate and which option might be the best fit.

Origin: YouTube / Diabetes Management (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.